Table 2.

Eradication Rates after Standard Triple and Bismuth-Quadruple Therapies According to the Type of Point Mutation

Types of first-line therapy	Negative point mutation	Positive point mutation A2142G	Positive point mutation A2143G or double*,†
Per-protocol
Standard triple	229/255 (89.8)	4/4 (100.0)	8/31 (25.8)
Bismuth-quadruple	2/2 (100.0)	9/9 (100.0)	105/114 (92.1)
Intention-to-treat
Standard triple	229/287 (79.8)	4/4 (100.0)	8/33 (24.2)
Bismuth-quadruple	2/2 (100.0)	9/10 (90.0)	109/128 (85.2)

Data are presented as number/total number (%).

*Double, both A2142G and A2143G; ^†p<0.05 for the per-protocol and intention-to-treat analyses between standard triple and quadruple therapies.